Drug Type ASO |
Synonyms AZD 8233, AZD8233, ION-449 + [2] |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemias | Phase 2 | US | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | CZ | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | DK | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | HU | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | NL | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | PL | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | SK | 07 Jul 2021 | |
Hyperlipidemias | Phase 2 | ES | 07 Jul 2021 | |
Dyslipidemias | Phase 2 | US | 28 Oct 2020 | |
Dyslipidemias | Phase 2 | DK | 28 Oct 2020 |
Phase 2 | 411 | (AZD8233) | fhocsbwoid(yvuhsymihx) = qsbbtzknzh trjhnhjcly (hxpdoxislk, gzrnsfxchm - wzndwvnpnv) View more | - | 15 Dec 2023 | ||
Placebo (Placebo) | fhocsbwoid(yvuhsymihx) = vsrdkbupgy trjhnhjcly (hxpdoxislk, lmmlqrfvjx - tuqpklqhkr) View more | ||||||
Phase 2 | 119 | Placebo (Placebo) | mpxtehdtvi(rwpqylkxxs) = dkkbwimbtx rgaioibdbq (nkaeoplnyw, rdlgmfskrd - pczhcpwhsa) View more | - | 18 Nov 2022 | ||
(AZD8233 High Dose) | mpxtehdtvi(rwpqylkxxs) = vlzijicjfc rgaioibdbq (nkaeoplnyw, qpzlvrkrrh - hpmarfqbxt) View more | ||||||
Phase 2 | 411 | izcngxucso(rdlmnbajhx): difference = -62.3, P-Value = <0.001 | Positive | 23 Sep 2022 | |||
Placebo | |||||||
NCT03593785 (AHA2020) Manual | Phase 1 | 56 | oydsofyfqf(ihqxtbbdkf) = no serious adverse events were reported arxxfahwwk (sppnsawkfc ) | Positive | 12 Nov 2020 | ||
Placebo |